- Home
- PTLO vs PHVS Comparison
PTLO vs PHVS Comparison
Compare PTLO & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTLO
- PHVS
- Stock Information
- Founded
- PTLO 1963
- PHVS 2015
- Country
- PTLO United States
- PHVS Switzerland
- Employees
- PTLO N/A
- PHVS N/A
- Industry
- PTLO Restaurants
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- PTLO Consumer Discretionary
- PHVS Health Care
- Exchange
- PTLO Nasdaq
- PHVS Nasdaq
- Market Cap
- PTLO 829.2M
- PHVS 980.9M
- IPO Year
- PTLO 2021
- PHVS 2021
- Fundamental
- Price
- PTLO $7.40
- PHVS $20.10
- Analyst Decision
- PTLO Buy
- PHVS Buy
- Analyst Count
- PTLO 8
- PHVS 6
- Target Price
- PTLO $13.38
- PHVS $37.17
- AVG Volume (30 Days)
- PTLO 3.4M
- PHVS 216.0K
- Earning Date
- PTLO 08-05-2025
- PHVS 08-13-2025
- Dividend Yield
- PTLO N/A
- PHVS N/A
- EPS Growth
- PTLO 17.90
- PHVS N/A
- EPS
- PTLO 0.46
- PHVS N/A
- Revenue
- PTLO $727,754,000.00
- PHVS N/A
- Revenue This Year
- PTLO $12.13
- PHVS N/A
- Revenue Next Year
- PTLO $13.86
- PHVS N/A
- P/E Ratio
- PTLO $16.94
- PHVS N/A
- Revenue Growth
- PTLO 3.62
- PHVS N/A
- 52 Week Low
- PTLO $7.20
- PHVS $11.51
- 52 Week High
- PTLO $15.78
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- PTLO 22.78
- PHVS 48.84
- Support Level
- PTLO $7.20
- PHVS $20.06
- Resistance Level
- PTLO $10.67
- PHVS $22.30
- Average True Range (ATR)
- PTLO 0.50
- PHVS 1.13
- MACD
- PTLO -0.32
- PHVS -0.23
- Stochastic Oscillator
- PTLO 5.41
- PHVS 22.84
About PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.